JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Accounts Payable & Accrued Expense: ฿97.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:JSP-R JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP-R
82 GF Score
Price ฿1.75
GF Value ฿2.18
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is JSP Pharmaceutical Manufacturing (Thailand) PCL Accounts Payable & Accrued Expense?

JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP-R +0.32% 82 Accounts Payable & Accrued Expense is ฿97.3 Mil as of Jun. 2026. GuruFocus rates BKK:JSP-R with a GF Score™ of 82/100 and a GF Value™ of ฿2.18 (Modestly Undervalued). The stock has 7 warning signs investors should review.

JSP Pharmaceutical Manufacturing (Thailand) PCL's quarterly accounts payable & accrued expense declined from Dec. 2025 (฿112.0 Mil) to Mar. 2026 (฿106.7 Mil) and declined from Mar. 2026 (฿106.7 Mil) to Jun. 2026 (฿97.3 Mil).

JSP Pharmaceutical Manufacturing (Thailand) PCL's annual accounts payable & accrued expense increased from Dec. 2023 (฿75.0 Mil) to Dec. 2024 (฿111.9 Mil) and increased from Dec. 2024 (฿111.9 Mil) to Dec. 2025 (฿112.0 Mil).

JSP Pharmaceutical Manufacturing (Thailand) PCL Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for JSP Pharmaceutical Manufacturing (Thailand) PCL's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JSP Pharmaceutical Manufacturing (Thailand) PCL Accounts Payable & Accrued Expense Chart

JSP Pharmaceutical Manufacturing (Thailand) PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial 69.36 77.51 75.05 111.88 111.99

JSP Pharmaceutical Manufacturing (Thailand) PCL Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 125.85 116.40 111.99 106.66 97.35
BKK:JSP-R
82GF Score
JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP-R
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JSP Pharmaceutical Manufacturing (Thailand) PCL Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of ฿97.3 Mil mean?
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) has a Accounts Payable & Accrued Expense of ฿97.3 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's Accounts Payable & Accrued Expense too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current Accounts Payable & Accrued Expense is ฿97.3 Mil. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's Accounts Payable & Accrued Expense compare to KHC and GIS?
JSP Pharmaceutical Manufacturing (Thailand) PCL's Accounts Payable & Accrued Expense of ฿97.3 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Consumer Packaged Goods company?
A good Accounts Payable & Accrued Expense depends on the Consumer Packaged Goods industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Accounts Payable & Accrued Expense is ฿97.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿2.18, compared to a current price of ฿1.75 — trading 19.9% below its estimated fair value. The current Accounts Payable & Accrued Expense is ฿97.3 Mil. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R), the current Accounts Payable & Accrued Expense is ฿97.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Overvalued in 2026?

Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued. The current stock price of ฿1.75 is trading 19.9% below its estimated GF Value™ of ฿2.18. GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Modestly Undervalued.

Key valuation signals for BKK:JSP-R:

  • Accounts Payable & Accrued Expense: ฿97.3 Mil
  • GF Value™: ฿2.18 vs. price of ฿1.75 (19.9% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the BKK:JSP-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JSP Pharmaceutical Manufacturing (Thailand) PCL Business Description

Other Exchanges JSP:Thailand
Address No. 255, 257 Soi Sathupradit 58, Bang Pongphang, Yan Nawa, Bangkok, THA, 10120
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
82GF Score

Get the complete analysis for BKK:JSP-R

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿1.75
Price
฿2.18
GF Value